COAG (Hemab Therapeutics Holdings) EV-to-FCF: (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COAG Hemab Therapeutics Holdings Inc COAG
11 GF Score
Price $46.52
! 2 Warning Signs
View Full Analysis

What is Hemab Therapeutics Holdings EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Hemab Therapeutics Holdings's Enterprise Value is $2,010.27 Mil. Hemab Therapeutics Holdings does not have enough years/quarters to calculate its Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Hemab Therapeutics Holdings's EV-to-FCF at this moment.

The historical rank and industry rank for Hemab Therapeutics Holdings's EV-to-FCF or its related term are showing as below:

COAG' s EV-to-FCF Range Over the Past 10 Years
Min: -34.39   Med: 0   Max: 0
Current: -32.69
COAG's EV-to-FCF is ranked worse than
100% of 348 companies
in the Biotechnology industry
Industry Median: 14.235 vs COAG: -32.69

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-08-04), Hemab Therapeutics Holdings's stock price is $46.52. Hemab Therapeutics Holdings does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Hemab Therapeutics Holdings's PE Ratio (TTM) at this moment.

Hemab Therapeutics Holdings  (NAS:COAG) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Hemab Therapeutics Holdings's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=46.52/
=

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Hemab Therapeutics Holdings EV-to-FCF Related Terms

Hemab Therapeutics Holdings EV-to-FCF Historical Data

* Premium members only.

The historical data trend for Hemab Therapeutics Holdings's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemab Therapeutics Holdings EV-to-FCF Chart

Hemab Therapeutics Holdings Annual Data
Trend Dec24 Dec25
EV-to-FCF
0.00 0.00

Hemab Therapeutics Holdings Semi-Annual Data
Dec24 Dec25
EV-to-FCF 0.00 0.00

COAG vs ZLAB, SLS, IOVA: EV-to-FCF Comparison

For the Biotechnology subindustry, Hemab Therapeutics Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hemab Therapeutics Holdings EV-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemab Therapeutics Holdings's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Hemab Therapeutics Holdings's EV-to-FCF falls into.


COAG
11GF Score
Hemab Therapeutics Holdings Inc COAG
EV-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hemab Therapeutics Holdings EV-to-FCF Calculation

Hemab Therapeutics Holdings's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=2010.270/
=

Hemab Therapeutics Holdings Business Description

Address 101 Main Street, Suite 1220, Cambridge, MA, USA, 02142
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
11GF Score

Get the complete analysis for COAG

EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$46.52
Price